Published by Josh White on 9th May 2024
(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.
URL: http://www.digitallook.com/dl/news/story/34281143/...